Patient Derived Xenograft (PDX) Models Global Market Report 2025

Description

Patient-derived xenograft (PDX) models involve the transplantation of human tumor tissue into immunodeficient animal hosts. These models replicate the complexity of human tumors more accurately than traditional cell line models. PDX models are essential for studying tumor biology and testing potential cancer therapies before they reach clinical trials.

The primary types in the patient-derived xenograft (PDX) models market are mice models and rat models. Mice models are laboratory mice that have been genetically modified or bred to study specific biological processes, diseases, or treatment responses, supporting biomedical and pharmaceutical research. The various techniques include heterotopic implantation and orthotopic implantation, and encompass several types of tumors such as gastrointestinal tumor models, lung tumor models, hematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, and others. PDX models are used in preclinical drug development, precision medicine, co-clinical trials, and basic cancer research by academic institutions, research organizations, pharmaceutical companies, biotechnology firms, and other entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The patient derived xenograft (PDX) models market research report is one of a series of new reports from The Business Research Company that provides patient derived xenograft (PDX) models market statistics, including the patient derived xenograft (PDX) models industry global market size, regional shares, competitors with patient derived xenograft (PDX) models market share, detailed patient derived xenograft (PDX) models market segments, market trends, and opportunities, and any further data you may need to thrive in the patient derived xenograft (PDX) models industry. These patient derived xenograft (PDX) models market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The patient derived xenograft (pdx) models market size has grown rapidly in recent years. It will grow from $0.4 billion in 2024 to $0.47 billion in 2025 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to research & development investments, regulatory support, partnerships and collaborations, increasing number of contract research organizations (CROs), and rising number of cancer cases.

The patient derived xenograft (pdx) models market size is expected to see rapid growth in the next few years. It will grow to $0.81 billion in 2029 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to demand for personalized medicine, rising in demand for humanized PDX models, growing incidence of cancer, focus on precision oncology, and increasing R&D investment for cancer research. Major trends in the forecast period include technological developments, rising demand for humanized PDX models, collaborative research initiatives, growing investments in cancer research, and increasing focus on immuno-oncology.

The forecast of 14.9% growth over the next five years reflects a modest reduction of 1.1% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of Patient-Derived Xenograft models sourced from China and Japan, thereby delaying oncology research and elevating cancer center expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The demand for personalized medicine is expected to drive the growth of the patient-derived xenograft (PDX) models market. Personalized medicine tailors medical treatments to individual patient characteristics, such as genetics, environment, and lifestyle. This demand is rising due to advancements in genomic research, which facilitate treatments based on individual genetic profiles, leading to more effective and targeted healthcare. PDX models support personalized medicine by testing individual patient tumors to predict treatment responses and tailor therapies. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the demand for personalized medicine fuels the growth of the PDX models market.

Major companies in the PDX models market are developing innovative models with in vivo bioluminescence imaging capabilities for real-time tumor growth monitoring. This imaging technique enhances PDX models by enabling non-invasive monitoring of tumor metastasis and treatment responses, improving the effectiveness of preclinical drug development research. For instance, in March 2024, InVitro Research Solutions Private Limited, an Indian Contract Research Organization (CRO), launched an innovative orthotopic model of human glioblastoma in NSG-SGM3 mice using PDX and in vivo bioluminescence imaging. This model aims to enable personalized treatment of glioblastoma, a highly aggressive brain cancer, and is critical for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve outcomes.

In October 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Modifi Biosciences, Inc., for $1.3 billion. This acquisition aligns with Merck's strategy to enhance its oncology portfolio by incorporating Modifi's innovative research, which includes preclinical drug candidates and patient-derived xenograft model data, aimed at advancing therapies for cancers with DNA repair deficiencies. Modifi Biosciences, Inc. is a US-based biotechnology company focused on developing cancer therapeutics that target cancer cells through direct DNA modification.

Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer , Pharmatest Services Ltd., IVRS AB, Altogen Inc

North America was the largest region in the patient derived xenograft (PDX) models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the patient derived xenograft (PDX) models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The patient derived xenograft (PDX) models market includes revenues earned by entities by providing services such as evaluating drug efficacy, studying tumor biology, and predicting patient-specific treatment responses in preclinical cancer research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Patient Derived Xenograft (PDX) Models Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on patient derived xenograft (pdx) models market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for patient derived xenograft (pdx) models ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The patient derived xenograft (pdx) models market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Mice Models; Rat Models
2) By Technique: Heterotopic Implantation; Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
Companies Mentioned: Laboratory Corporation of America Holdings; WuXi AppTec Co. Ltd.; Charles River Laboratories International Inc.; The Jackson Laboratory; Inotiv Inc; Biocytogen Pharmaceuticals Co. Ltd.; Taconic Biosciences Inc; BioDuro-Sundia Inc; Horizon Discovery Ltd.; Crown Bioscience Inc.; Champions Oncology Inc.; Oncodesign Services S.A; Genesis Biotechnology Group LLC.; Creative Animodel; Abnova Corp.; Certis Oncology Solutions Inc.; Xentech; Aragen Bioscience Inc.; EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH.; Urosphere; Hera BioLabs; InnoSer ; Pharmatest Services Ltd.; IVRS AB; Altogen Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r30900u

1. Executive Summary

2. Patient Derived Xenograft (PDX) Models Market Characteristics

3. Patient Derived Xenograft (PDX) Models Market Trends And Strategies

4. Patient Derived Xenograft (PDX) Models Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Patient Derived Xenograft (PDX) Models Growth Analysis And Strategic Analysis Framework

5.1. Global Patient Derived Xenograft (PDX) Models PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Patient Derived Xenograft (PDX) Models Market Growth Rate Analysis
5.4. Global Patient Derived Xenograft (PDX) Models Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Patient Derived Xenograft (PDX) Models Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Patient Derived Xenograft (PDX) Models Total Addressable Market (TAM)

6. Patient Derived Xenograft (PDX) Models Market Segmentation

6.1. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mice Models
Rat Models
6.2. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Heterotopic Implantation
Orthotropic Implantation
6.3. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastrointestinal Tumor Models
Lung Tumor Models
Hematological Tumor Models
Gynecological Tumor Models
Respiratory Tumor Models
Urological Tumor Models
Other Tumor Models
6.4. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preclinical Drug Development
Precision Medicine
Co-Clinical Trials
Basic Cancer Research
6.5. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Academic And Research Organizations
Contract Research Organizations
Pharmaceutical And Biotechnological Companies
Other End-Users
6.6. Global Patient Derived Xenograft (PDX) Models Market, Sub-Segmentation Of Mice Models, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunodeficient Mice Models (Nude Mice, SCID Mice)
Humanized Mice Models
Genetically Modified Mice Models
6.7. Global Patient Derived Xenograft (PDX) Models Market, Sub-Segmentation Of Rat Models, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunodeficient Rat Models
Humanized Rat Models
Genetically Modified Rat Models

7. Patient Derived Xenograft (PDX) Models Market Regional And Country Analysis

7.1. Global Patient Derived Xenograft (PDX) Models Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Patient Derived Xenograft (PDX) Models Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Patient Derived Xenograft (PDX) Models Market

8.1. Asia-Pacific Patient Derived Xenograft (PDX) Models Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Patient Derived Xenograft (PDX) Models Market

9.1. China Patient Derived Xenograft (PDX) Models Market Overview
9.2. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Patient Derived Xenograft (PDX) Models Market

10.1. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Patient Derived Xenograft (PDX) Models Market

11.1. Japan Patient Derived Xenograft (PDX) Models Market Overview
11.2. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Patient Derived Xenograft (PDX) Models Market

12.1. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Patient Derived Xenograft (PDX) Models Market

13.1. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Patient Derived Xenograft (PDX) Models Market

14.1. South Korea Patient Derived Xenograft (PDX) Models Market Overview
14.2. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Patient Derived Xenograft (PDX) Models Market

15.1. Western Europe Patient Derived Xenograft (PDX) Models Market Overview
15.2. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Patient Derived Xenograft (PDX) Models Market

16.1. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Patient Derived Xenograft (PDX) Models Market

17.1. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Patient Derived Xenograft (PDX) Models Market

18.1. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Patient Derived Xenograft (PDX) Models Market

19.1. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Patient Derived Xenograft (PDX) Models Market

20.1. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Patient Derived Xenograft (PDX) Models Market

21.1. Eastern Europe Patient Derived Xenograft (PDX) Models Market Overview
21.2. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Patient Derived Xenograft (PDX) Models Market

22.1. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Patient Derived Xenograft (PDX) Models Market

23.1. North America Patient Derived Xenograft (PDX) Models Market Overview
23.2. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Patient Derived Xenograft (PDX) Models Market

24.1. USA Patient Derived Xenograft (PDX) Models Market Overview
24.2. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Patient Derived Xenograft (PDX) Models Market

25.1. Canada Patient Derived Xenograft (PDX) Models Market Overview
25.2. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Patient Derived Xenograft (PDX) Models Market

26.1. South America Patient Derived Xenograft (PDX) Models Market Overview
26.2. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Patient Derived Xenograft (PDX) Models Market

27.1. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Patient Derived Xenograft (PDX) Models Market

28.1. Middle East Patient Derived Xenograft (PDX) Models Market Overview
28.2. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Patient Derived Xenograft (PDX) Models Market

29.1. Africa Patient Derived Xenograft (PDX) Models Market Overview
29.2. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Patient Derived Xenograft (PDX) Models Market Competitive Landscape And Company Profiles

30.1. Patient Derived Xenograft (PDX) Models Market Competitive Landscape
30.2. Patient Derived Xenograft (PDX) Models Market Company Profiles
- 30.2.1. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Inotiv Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Patient Derived Xenograft (PDX) Models Market Other Major And Innovative Companies

31.1. Biocytogen Pharmaceuticals Co. Ltd.
31.2. Taconic Biosciences Inc.
31.3. BioDuro-Sundia Inc.
31.4. Horizon Discovery Ltd.
31.5. Crown Bioscience Inc.
31.6. Champions Oncology Inc.
31.7. Oncodesign Services S.A.
31.8. Genesis Biotechnology Group LLC.
31.9. Creative Animodel
31.10. Abnova Corp.
31.11. Certis Oncology Solutions Inc.
31.12. Xentech
31.13. Aragen Bioscience Inc.
31.14. EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH.
31.15. Urosphere

32. Global Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Patient Derived Xenograft (PDX) Models Market

34. Recent Developments In The Patient Derived Xenograft (PDX) Models Market

35. Patient Derived Xenograft (PDX) Models Market High Potential Countries, Segments and Strategies

35.1 Patient Derived Xenograft (PDX) Models Market In 2029 - Countries Offering Most New Opportunities
35.2 Patient Derived Xenograft (PDX) Models Market In 2029 - Segments Offering Most New Opportunities
35.3 Patient Derived Xenograft (PDX) Models Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer